Tired of clinical trials sinking $800 million to $1.4 billion and taking 10-15 years to bring a single new drug to market, with high failure rates contributing significantly to inefficiency? Discover how Artificial Intelligence (AI) is revolutionizing drug development, tackling main causes of failure like suboptimal patient selection, recruiting, and monitoring

Get ready for a paradigm shift in oncology! AstraZeneca and Modella AI have officially launched a groundbreaking, multi-year agreement to supercharge AI-driven cancer clinical development worldwide. This exciting collaboration grants AstraZeneca unparalleled access to Modella AI's cutting-edge, multi-modal foundation models, designed to extract rich features from diverse data types and accelerate every aspect of clinical development across their global oncology portfolio. Witness the future of medicine as this partnership aims to enhance biomarker discovery, streamline clinical development, and ultimately transform patient outcomes. With AI deeply integrated into their strategy, AstraZeneca is confident in increasing the probabilities of success in their oncology clinical trials. This isn't just an agreement; it's a powerful leap forward for precision medicine, promising unprecedented speed and the potential to automate complex R&D workflows for a brighter, healthier future!

Learn how global crises, from Brexit and COVID-19 to cybersecurity threats and natural disasters, are challenging clinical trial teams. Discover how proactivity, flexibility, collaboration, and IRT technology are key to minimizing participant disruption and ensuring study continuity in turbulent times.